Cargando…

A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease

INTRODUCTION: Use of biological therapies may reduce or delay the surgical procedures in patients with inflammatory bowel disease (IBD). The aim of this meta-analysis and systematic review was to determine the impact of pre-operative infliximab (IFX) use on the rate of surgical interventions in pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehteshami-Afshar, Solmaz, Nikfar, Shekoufeh, Rezaie, Ali, Abdollahi, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2011
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3264992/ https://www.ncbi.nlm.nih.gov/pubmed/22328883 http://dx.doi.org/10.5114/aoms.2011.26612

Ejemplares similares

Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn’s Disease? A Meta-analysis of Controlled Clinical Trials
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis
por: Rezaie, Ali, et al.
Publicado: (2010)

Current opinion on treatment of inflammatory bowel disease in pregnant women
por: Salari, Pooneh, et al.
Publicado: (2012)

Are probiotics effective in management of irritable bowel syndrome?
por: Hosseini, Asieh, et al.
Publicado: (2012)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Efficacy and tolerability of renzapride in irritable bowel syndrome: a meta-analysis of randomized, controlled clinical trials including 2528 patients
por: Mozaffari, Shilan, et al.
Publicado: (2014)

Potential Vaccines for Treating Crohn's Disease
por: Rostami-Nejad, Mohammad, et al.
Publicado: (2020)

Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions
por: Abdollahias, Akbar, et al.
Publicado: (2011)

Achieving Equitable Access to Medicines and Health Services: A COVID-19-time Recalled Matter
por: Mousavi, Taraneh, et al.
Publicado: (2021)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Benefits of Zataria multiflora Boiss in Experimental Model of Mouse Inflammatory Bowel Disease
por: Nakhai, Leila Ashtaral, et al.
Publicado: (2007)

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Does infliximab increase complications after surgery for inflammatory bowel disease?
por: Holubar, Stefan D, et al.
Publicado: (2009)

Impact of Atrial Fibrillation on Patients With Inflammatory Bowel Disease Admitted for Colectomy
por: Mahfouz, Ratib, et al.
Publicado: (2022)

Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran
por: Nikfar, Shekoufeh, et al.
Publicado: (2005)

Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis
por: Nikfar, Shekoufeh, et al.
Publicado: (2012)

Tumor Necrosis Factor-alpha Antibodies in Fistulizing Crohn's Disease: An Updated Systematic Review and Meta-analysis
por: Zaboli, Pardis, et al.
Publicado: (2017)

Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan
por: Sagami, Shintaro, et al.
Publicado: (2021)

Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
por: Bouhnik, Yoram, et al.
Publicado: (2022)

A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer
por: Yazdi, Mohammad Hossein, et al.
Publicado: (2015)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Efficacy, functional outcome and post-operative complications of total abdominal colectomy with ileorectal anastomosis vs. segmental colectomy in hereditary non-polyposis colorectal cancer
por: Sun, Jie, et al.
Publicado: (2018)

Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
por: Jukic, Tomislav, et al.
Publicado: (2023)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

COVID-19 mRNA Vaccines and Interstitial Lung Disease Exacerbation: Causation or Just a Temporal Association?
por: Ehteshami-Afshar, Solmaz, et al.
Publicado: (2022)

A model for developing a decision support system to simulate national drug policy indicators
por: Abdollahiasl, Akbar, et al.
Publicado: (2011)

Pattern of Antidepressant Utilization and Cost in Iran from 2006 to 2013 in Comparison with Other Countries
por: Soleymani, Fatemeh, et al.
Publicado: (2018)

The Effect of Barbed Sutures on Complication Rates Post Colectomy: A Retrospective Case-Matched Review
por: Ward, Haven, et al.
Publicado: (2022)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Infliximab-Associated Acneiform Eruption in a Patient With Inflammatory Bowel Disease
por: Khatana, Usman Feroze, et al.
Publicado: (2021)

Consistent defined threshold and equity in health
por: Nikfar, Shekoufeh, et al.
Publicado: (2015)

Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
por: Mohammad Sadeghi, Hosna, et al.
Publicado: (2021)

Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab
por: De Cristofaro, Elena, et al.
Publicado: (2022)

A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience
por: Keshavarz, Khosro, et al.
Publicado: (2013)

Bioactive Foods and Medicinal Plants for Cardiovascular Complications of Type II Diabetes: Current Clinical Evidence and Future Perspectives
por: Bahramsoltani, Roodabeh, et al.
Publicado: (2021)

Alternative specimen extraction techniques after laparoscopic emergency colectomy in inflammatory bowel disease
por: Gardenbroek, Tjibbe J., et al.
Publicado: (2011)

Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study
por: Wang, Xiaolei, et al.
Publicado: (2019)

A review on inputs and outputs in determining the efficiency of universities of medical sciences by data envelopment analysis method
por: Mojahedian, Mohammad M., et al.
Publicado: (2020)

Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases
por: Rezaie, Ali
Publicado: (2014)

Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies
por: Rezvanfar, Mohammad Ali, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_blj6hbnd7lgtg8vv9vendfls62